Tempo Bioscience Expands Patient-Relevant iPSC-Derived Cell Models

These five new products add to the already-existing Tempo Bioscience product line and expand TempoStemBank^™-iPSC offerings: 1) neurons and glia in the central nervous system; 2) neurons in the peripheral nervous system; 3) keratinocytes and melanocytes in the skin; 4) hepatocytes in the liver; and 5) retinal pigment epithelium cells in the eye. TempoATP^™, TempoMito^™, and TempoVol^™ biosensors are live-cell reporters of cellular, mitochondrial, and cytotoxicity functions.

Tempo Bioscience is the sole manufacturer of human iPSC-derived cell models that are engineered using non-viral, nucleic-acids-free, serum-free, and feeder-free technologies. Tempo is committed to advancing technologies that focus on disease modeling and drug safety evaluations using advanced human iPSC-derived cell models in 2D and 3D. Tempo’s patient-relevant cell models aim to improve drug efficacy evaluations and safety assessments during drug development.

The ultimate goal of Tempo Bioscience is to improve the drug development process, utilizing advanced patient-relevant cell models and clinically relevant computational modeling, to maximize efficiency, and to reduce overall development cost.

About Tempo Bioscience, Inc.: Founded in 2013, Tempo is a technology development biotechnology company based in San Francisco, California. Tempo develops and manufactures human iPSC-based biosensor enabling technologies for the biotech, pharmaceutical, and consumer product industries. For more information on Tempo, please visit our home page: <http://www.tempobioscience.com>. Follow us on LinkedIn, Twitter (@TempoBioscience) and TempoBlog.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190410005148/en/